Challenges in development of Cell/Gene Therapy Products (ATMPs) – Intellectual Property Do’s and Don’ts

Regulated as pharmaceuticals with a requirement for market approval, ATMPs (cell and/or gene therapy products) need to have a strong business model to survive costs of high-risk development, GMP manufacture and clinical trials. Partnering with commercial entities can often assist in your GMP translation, CMC, device and clinical trials development, but your partners need confirmation of protection for the commercial opportunity of a product – and the most obvious way to secure this is by patenting.

What to do, what not to do and what support is available? This is what you will get from this webinar on patentability and IP related to ATMPs. Presented by Joanna Applequist, European Patent Attorney; Ylva Wikmark, Patent Attorney; and Senior Attorney at Law Louise Jonshammar from AWA Sweden and hosted by NextCell Pharma’s CEO Mathias Svahn will discuss some of the tricks to protecting your ATMP IP and the ’what would have been good to have knowns’ that will set you on the right track to a viable commercial model.

The panel will touch on the following questions during the webinar:

• What types of intellectual property are available for your cell or gene therapy-based ATMP process?
• How can you ensure that the public funding of your research is used to create results relevant for a viable pharmaceutical for patients in need?
• What do you need to secure in agreements with your partners, researchers, investors and others, before initiating collaborations?

Please click here to register